Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Hubei Biocause Heilen Pharmaceutical Co. Ltd. stock ¥1.11, price ¥10.94, upside -89.9%, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 25, 2026.
How to read this chart
58‑month range ¥8.78 – ¥30.01 · fair‑value band ¥0.8300 – ¥1.39 · the ¥10.94 price screens above the ¥1.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 25, 2026.
Follow Hubei Biocause Heilen Pharmaceutical Co. in your weekly email
Every Wednesday you see whether Hubei Biocause Heilen Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally.
Show moreShow less
It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services.
The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations.
In addition, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates; antipyretic and analgesic, cardiovascular and anti-infective preparations; and chemicals and formulations.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. was founded in 1995 and is based in Jingmen, China.
Stock analysis
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) currently trades at ¥10.94, while our model-based Fair Value estimate is ¥1.11, 89.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥5.02 per share, and 1 of the 13 models we run sit above the ¥10.94 price.
Bear case: the Earnings-Based group reads lowest at ¥0.3400, and 12 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.8300 (bear) to ¥1.39 (bull), the price of ¥10.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. reported revenue of 453M CNY in FY2025 versus 541M CNY in FY2021, a compound −4.3%/yr. Reported net income was 34.9M CNY in FY2025, compounding −26.8%/yr from FY2021.
Key figures
Market cap 4.6B CNY (≈ $686M) Small · P/E ratio 99.5 · P/S ratio 9.80 · EPS (TTM) ¥0.1100 · Dividend yield 0.5% · Net margin 10.0% · Return on equity 2.1% · Return on assets (EBIT) 4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −23% fair-value upside, at −90%, 301211 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.3400 to ¥23.74). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥0.8300Fair Value ¥1.11Bull¥1.39
Price ¥10.94 · Upside -89.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0408 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−26.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−26.5%
Dividend (yield on the price)0.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.34% → 2%
⚠ Revenue per share shrinking 7.0%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Hubei Biocause Heilen Pharmaceutical Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 575 stocks
Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−89.9% · Bottom 25%
Profitability
Return on equity (12 months)2.1% · Below median
Return on assets1.5% · Below median
Net margin (12 months)10.0% · Above median
Operating margin (12 months)5.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)5.8% · Above median
Dividend yield (12 months)0.5% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)99.5× · Priciest 25%
P/B2.01× · Pricier than median
P/S (12 months)9.80× · Priciest 25%
EV/EBITDA76.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 21
FUTURE (revenue growth)29· sector 26
PAST (return on equity)8· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)11· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) overvalued or undervalued?
As of Oct 25, 2026, our model estimates a fair value of ¥1.11 versus a price of ¥10.94, about −90% upside (overvalued).
What is the fair value of 301211?
Our model-based fair value for Hubei Biocause Heilen Pharmaceutical Co. Ltd. is ¥1.11 (as of Oct 25, 2026), built from audited fundamentals. The current price: ¥10.94.
What is the quality score of 301211?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Our model-based price target is the fair value of ¥1.11 (as of Oct 25, 2026) from 13 valuation models. Cautious scenario ¥0.8300, optimistic scenario ¥1.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Hubei Biocause Heilen Pharmaceutical Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥1.11, about −90% upside versus a price of ¥10.94 (overvalued). Cautious scenario ¥0.8300, optimistic scenario ¥1.39. The calculation is refreshed regularly with new filings.
What is the revenue of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. reported trailing-twelve-month revenue of about 466M CNY (latest available figure, as of Oct 25, 2026).
Does Hubei Biocause Heilen Pharmaceutical Co. Ltd. pay a dividend?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. currently shows a dividend yield of 0.55% relative to its recent price (as of Oct 25, 2026).
What is the intrinsic value of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hubei Biocause Heilen Pharmaceutical Co. Ltd. it is ¥1.11 per share (as of Oct 25, 2026), against a price of ¥10.94. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Hubei Biocause Heilen Pharmaceutical Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 25, 2026, 301211 trades above its calculated fair value: price ¥10.94, fair value ¥1.11, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301211?
No. The price is what the market pays today (¥10.94); the fair value is what the company's own numbers justify (¥1.11). For Hubei Biocause Heilen Pharmaceutical Co. Ltd. the two are ¥9.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hubei Biocause Heilen Pharmaceutical Co. Ltd. worth?
The market values Hubei Biocause Heilen Pharmaceutical Co. Ltd. at about 4.6B CNY (market capitalisation, as of Oct 25, 2026). Per share that is ¥10.94; our models calculate a fair value of ¥1.11 per share.
What do the bullish and bearish scenarios say about 301211?
Our models span a range for Hubei Biocause Heilen Pharmaceutical Co. Ltd.: cautious scenario ¥0.8300, base ¥1.11, optimistic ¥1.39 per share (as of Oct 25, 2026, price ¥10.94). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301211?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. trades at a price-to-earnings ratio of 99.5 (as of Oct 25, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥1.11 is built from several models across several years. Other multiples: P/B 2.0, P/S 9.8, EV/EBITDA 76.1.
How solid is the balance sheet of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Balance-sheet figures for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (as of Oct 25, 2026): return on equity 2.1%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 301211 from its 52-week high?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. trades at ¥10.94, about 31% below its 52-week high of ¥15.93 and 18% above the low of ¥9.28 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.11 is for.
Which stocks are comparable to Hubei Biocause Heilen Pharmaceutical Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hubei Biocause Heilen Pharmaceutical Co. Ltd. stock attractive at the current price?
The data as of Oct 25, 2026: price ¥10.94, calculated fair value ¥1.11 (−90%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301211 calculated?
We run Hubei Biocause Heilen Pharmaceutical Co. Ltd. through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.11, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Hubei Biocause Heilen Pharmaceutical Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The closing price on Oct 23, 2026 was ¥10.94. Our model-based fair value is ¥1.11, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hubei Biocause Heilen Pharmaceutical Co. Ltd. right now?
The price sits above even our optimistic bull case (¥1.39). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Hubei Biocause Heilen Pharmaceutical Co. Ltd.
How large is the market capitalisation of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The market capitalisation of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 4.6B CNY (≈ $686M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The price-to-sales ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 9.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Earnings per share at Hubei Biocause Heilen Pharmaceutical Co. Ltd. are ¥0.1100 (price ÷ EPS = P/E 99.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The dividend yield of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 0.5% (payout 54.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The net margin of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 10.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The return on equity (ROE) of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
On an EBIT basis the return on assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
The operating margin of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Revenue at Hubei Biocause Heilen Pharmaceutical Co. Ltd. is growing +5.8% versus a year earlier (3y avg −4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)?
Earnings per share at Hubei Biocause Heilen Pharmaceutical Co. Ltd. are growing +161% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) generate?
The free cash flow of Hubei Biocause Heilen Pharmaceutical Co. Ltd. is −44.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) hold?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. holds more cash than debt, 540M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Hubei Biocause Heilen Pharmaceutical Co. Ltd. in the live analysis
One click puts Hubei Biocause Heilen Pharmaceutical Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 25, 2026